FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280585753> ?p ?o ?g. }

• W4280585753 abstract "Advanced ovarian cancer (AOC) and its treatment cause several symptoms and impact on patients' health-related quality of life (HRQoL). We aim to reach a consensus on the most relevant patient-reported outcome (PROs), the corresponding measures (PROMs), and measurement frequency during AOC patients' follow-up from patients' and healthcare professionals' (HCP) perspective.The project comprised five steps: 1) a literature review, 2) a focus group with patients, 3) a nominal group with HCP, 4) two round-Delphi consultations with patients and HCP, and 5) a final meeting with HCP. Delphi questionnaire was elaborated based on literature review, focus group (n=5 patients), and nominal group (n=16 HCP). The relevance of each PRO and the appropriateness (A) and feasibility (F) of the proposed PROM were assessed (Likert scale 1=strongly agree; 9=strongly disagree). The consensus was reached when at least 75% of the panelists rated it as 'relevant', 'appropriate', or 'feasible' (score 7-9).A total of 56 HCP [51.8% Hospital Pharmacy; 41.1% Oncology; 3.6% Nursing; and 3.6% Psycho-oncology; mean time in specialty 12.5 (8.0) years] and 10 AOC patients [mean time diagnosis 5.4 (3.0) years] participated in the 1st round. All PROs achieved consensus regarding their relevance, except dry skin (58.0%). Agreement was reached for PRO-CTCAE to be used to assess fatigue (A:84.9%; F:75.8%), neuropathy (A:92.4%; F:77.3%), diarrhea (A:87.9%; F:88.7%), constipation (A:86.4%; F:75.8%), nausea (A:89.4%; F:75.8%), insomnia (A:81.8%; F:88.7%), abdominal bloating (A:82.2%; F:82.2%) and sexuality (A:78.8%; F:88.6%); EQ-5D to determine patients' HRQoL (A:87.9%; F:80.3%), pain (A:87.9%; F:75.8%) and mood (A:77.7%; F:85.5%); to assess treatment adherence the Morisky-Green (A:90.9%; F:84.9%) and the dispensing register (A:80.3%; F:80.3%) were chosen. It was agreed to note in the medical record whether the patient's treatment preferences had been considered during decision-making (A:78.8%; F:78.8%) and to use a 5-point Likert scale to assess treatment satisfaction (A:86.4%; F:86.4%). Panelists agreed (A:92.4%; F: 77.3%) to collect these PROs (1) at the time of diagnosis/relapse; (2) one month after starting treatment/change therapeutic strategy; (3) every three months during the 1st-year of treatment; and later (4) every six months until treatment completion/change.The consensus reached represents the first step towards including the patient's perspective in AOC follow-up. The standardized collection of PROs in clinical practice may contribute to optimizing the follow-up of these patients and thus improving the quality of care." @default.
• W4280585753 created "2022-05-22" @default.
• W4280585753 creator A5027214834 @default.
• W4280585753 creator A5031729850 @default.
• W4280585753 creator A5032312831 @default.
• W4280585753 creator A5036747390 @default.
• W4280585753 creator A5039616996 @default.
• W4280585753 creator A5045414527 @default.
• W4280585753 creator A5049004520 @default.
• W4280585753 creator A5053768135 @default.
• W4280585753 creator A5055388509 @default.
• W4280585753 creator A5064871091 @default.
• W4280585753 creator A5067863599 @default.
• W4280585753 creator A5071775419 @default.
• W4280585753 creator A5072047819 @default.
• W4280585753 creator A5076943161 @default.
• W4280585753 creator A5078047464 @default.
• W4280585753 creator A5086186160 @default.
• W4280585753 creator A5090906445 @default.
• W4280585753 date "2022-05-18" @default.
• W4280585753 modified "2023-10-16" @default.
• W4280585753 title "Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer" @default.
• W4280585753 cites W1771332781 @default.
• W4280585753 cites W1971039699 @default.
• W4280585753 cites W1975219646 @default.
• W4280585753 cites W1982511475 @default.
• W4280585753 cites W2017265038 @default.
• W4280585753 cites W2028398671 @default.
• W4280585753 cites W2031756259 @default.
• W4280585753 cites W2034204383 @default.
• W4280585753 cites W2041414510 @default.
• W4280585753 cites W2070309415 @default.
• W4280585753 cites W2091310835 @default.
• W4280585753 cites W2101713088 @default.
• W4280585753 cites W2132483348 @default.
• W4280585753 cites W2156635540 @default.
• W4280585753 cites W2162645859 @default.
• W4280585753 cites W2221484896 @default.
• W4280585753 cites W2268828514 @default.
• W4280585753 cites W2413971556 @default.
• W4280585753 cites W2438866487 @default.
• W4280585753 cites W2568091290 @default.
• W4280585753 cites W2766420394 @default.
• W4280585753 cites W2778746938 @default.
• W4280585753 cites W2894826729 @default.
• W4280585753 cites W3021019568 @default.
• W4280585753 cites W3023274953 @default.
• W4280585753 cites W3082782539 @default.
• W4280585753 cites W4250968058 @default.
• W4280585753 doi "https://doi.org/10.3389/fonc.2022.885910" @default.
• W4280585753 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35664764" @default.
• W4280585753 hasPublicationYear "2022" @default.
• W4280585753 type Work @default.
• W4280585753 citedByCount "1" @default.
• W4280585753 countsByYear W42805857532023 @default.
• W4280585753 crossrefType "journal-article" @default.
• W4280585753 hasAuthorship W4280585753A5027214834 @default.
• W4280585753 hasAuthorship W4280585753A5031729850 @default.
• W4280585753 hasAuthorship W4280585753A5032312831 @default.
• W4280585753 hasAuthorship W4280585753A5036747390 @default.
• W4280585753 hasAuthorship W4280585753A5039616996 @default.
• W4280585753 hasAuthorship W4280585753A5045414527 @default.
• W4280585753 hasAuthorship W4280585753A5049004520 @default.
• W4280585753 hasAuthorship W4280585753A5053768135 @default.
• W4280585753 hasAuthorship W4280585753A5055388509 @default.
• W4280585753 hasAuthorship W4280585753A5064871091 @default.
• W4280585753 hasAuthorship W4280585753A5067863599 @default.
• W4280585753 hasAuthorship W4280585753A5071775419 @default.
• W4280585753 hasAuthorship W4280585753A5072047819 @default.
• W4280585753 hasAuthorship W4280585753A5076943161 @default.
• W4280585753 hasAuthorship W4280585753A5078047464 @default.
• W4280585753 hasAuthorship W4280585753A5086186160 @default.
• W4280585753 hasAuthorship W4280585753A5090906445 @default.
• W4280585753 hasBestOaLocation W42805857531 @default.
• W4280585753 hasConcept C105776082 @default.
• W4280585753 hasConcept C111919701 @default.
• W4280585753 hasConcept C126322002 @default.
• W4280585753 hasConcept C131872663 @default.
• W4280585753 hasConcept C138496976 @default.
• W4280585753 hasConcept C144133560 @default.
• W4280585753 hasConcept C15744967 @default.
• W4280585753 hasConcept C159110408 @default.
• W4280585753 hasConcept C162853370 @default.
• W4280585753 hasConcept C1862650 @default.
• W4280585753 hasConcept C2777364248 @default.
• W4280585753 hasConcept C2779495148 @default.
• W4280585753 hasConcept C2779517570 @default.
• W4280585753 hasConcept C2779951463 @default.
• W4280585753 hasConcept C2780580376 @default.
• W4280585753 hasConcept C41008148 @default.
• W4280585753 hasConcept C512399662 @default.
• W4280585753 hasConcept C56995899 @default.
• W4280585753 hasConcept C71924100 @default.
• W4280585753 hasConceptScore W4280585753C105776082 @default.
• W4280585753 hasConceptScore W4280585753C111919701 @default.
• W4280585753 hasConceptScore W4280585753C126322002 @default.
• W4280585753 hasConceptScore W4280585753C131872663 @default.
• W4280585753 hasConceptScore W4280585753C138496976 @default.
• W4280585753 hasConceptScore W4280585753C144133560 @default.
• W4280585753 hasConceptScore W4280585753C15744967 @default.

• next